# Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

> **NCT04428073** · PHASE1 · UNKNOWN · sponsor: **GeneCure Biotechnologies** · enrollment: 32 (estimated)

## Conditions studied

- COVID

## Interventions

- **BIOLOGICAL:** Covax-19™

## Key facts

- **NCT ID:** NCT04428073
- **Lead sponsor:** GeneCure Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07
- **Primary completion:** 2021-07
- **Final completion:** 2021-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428073, "Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04428073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*